Tirzepatide

Tirzepatide is a novel once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP-1R) agonist developed by Eli Lilly and Company. It represents a new class of antidiabetic medications known as dual incretin agonists.

Key Benefits

• Mechanism of action
  Tirzepatide activates both the GIP receptor and the GLP-1 receptor, which are involved in the regulation of blood sugar levels. By activating these receptors, tirzepatide stimulates the release of insulin, inhibits the release of glucagon, slows gastric emptying, and promotes satiety, leading to improved glycemic control.

• Clinical trials
  Tirzepatide has demonstrated promising results in clinical trials for the treatment of type 2 diabetes mellitus (T2DM). In Phase 3 trials, tirzepatide has shown superior efficacy in lowering HbA1c levels and reducing body weight compared to other antidiabetic medications, including insulin glargine and dulaglutide.

• Efficacy
  Tirzepatide has shown robust efficacy in reducing HbA1c levels, a measure of long-term blood glucose control, as well as body weight in patients with T2DM. Its dual mechanism of action targeting both GIP and GLP-1 pathways may offer additional benefits compared to single-receptor agonists.

• Weight loss
  One notable aspect of tirzepatide is its significant weight loss effect. In clinical trials, patients treated with tirzepatide experienced substantial reductions in body weight, which may be attributed to its effects on reducing appetite and promoting satiety.

• Safety
  Overall, tirzepatide has been well-tolerated in clinical trials, with the most common adverse events including gastrointestinal symptoms such as nausea and vomiting. Hypoglycemia (low blood sugar) rates were low, particularly compared to insulin therapy.

• Future implications
  Tirzepatide holds promise as a potential treatment option for patients with T2DM, especially those who struggle to achieve glycemic control and weight management with existing therapies. Its once-weekly dosing regimen may also improve treatment adherence and convenience for patients.

Starter Protocol
Tirzepatide Starter Vial
(Tirzepatide Sterile Solution 10 mg/0.5 mL + Pyridoxine (B6) 1 mg/0.5 mL)
10 mg/0.5 mL in 3 mL
💰 $1,400 – 16-week supply

Continuation Protocol
Tirzepatide Continuation Doses
(Tirzepatide Sterile Solution 10 mg/0.5 mL + Pyridoxine (B6) 1 mg/0.5 mL)
10 mg/0.5 mL in 3 mL
💰 $1,400

• 12.5 units / 0.125 mL / 2.5 mg — vial will last 24 weeks

• 25 units / 0.25 mL / 5 mg — vial will last 12 weeks

• 37.5 units / 0.375 mL / 7.5 mg — vial will last 8 weeks

• 50 units / 0.5 mL / 10 mg — vial will last 6 weeks

Prescription Type

• Injection

Prescriptions require a $25 non-refundable physician fee that covers clinical analysis of blood tests, physician protocol recommendations, access to Elivate staff and office visits. Physician fee is paid prior physician consultation.